News & Updates

Veliparib continues to show positive signals in ovarian cancer

08 May 2020 by

Subgroup analyses of the VELIA* trial showed that the concomitant administration of the poly(adenosine diphosphate-ribose) polymerase inhibitor veliparib with an induction chemotherapy (CT) regimen comprising carboplatin and paclitaxel (CP) generated antitumour activity and favourable safety in women with high-grade serous ovarian cancer.

Veliparib continues to show positive signals in ovarian cancer

08 May 2020

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Elderly patients of pancreatic ductal adenocarcinoma suffer from worse health-related quality of life (HRQoL), particularly in terms of physical health status, a recent study has found.

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020 by

The use of durvalumab in combination with olaparib and paclitaxel significantly improves pathological complete response (pCR) rate vs paclitaxel alone in patients with high-risk HER2-negative stage II/III breast cancer, new results of the I-SPY 2 trial have shown.

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020

$Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM$

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

06 May 2020

Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

06 May 2020

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

06 May 2020

Low preoperative prognostic nutritional index (PNI) has a significant impact on the completion of planned adjuvant chemotherapy (AC) following curative resection of stage II/III gastric cancer, a study has shown. Low PNI and incomplete AC confer an additive effect and lead to worse outcomes.

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

06 May 2020

Long-term PPI use does not increase GI cancer risk

06 May 2020 by

Use of proton-pump inhibitors (PPIs) for ≥2 years is not associated with a higher risk of gastrointestinal cancers, while the association of PPI use of ≥10 years with cancer risk remains unclear, reveals a study.

Long-term PPI use does not increase GI cancer risk

06 May 2020

Any polyps spell risk of colorectal cancer

05 May 2020 by

Patients with any subtypes of polyps had a greater risk of developing colorectal cancer (CRC) than the general population in a largely screening-naive Swedish cohort, indicating that CRC risk is not limited to just those with advanced histology, reveals a large registry-based study.

Any polyps spell risk of colorectal cancer

05 May 2020

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

05 May 2020

The rate of polypharmacy is high among patients with multiple myeloma, according to a study. However, comanagement with a pharmacist reduces the number of all medications, particularly those that are not related to myeloma.

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

05 May 2020

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

04 May 2020

MuGard and Caphosol do not appear to be more effective than standard topical therapy at reducing pain scores or increasing mucosal recovery in the treatment of chemotherapy-induced oral mucositis, a recent study has shown.

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

04 May 2020

Liquid biopsy promising for multidrug resistance detection in multiple myeloma

04 May 2020 by

Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.

Liquid biopsy promising for multidrug resistance detection in multiple myeloma

04 May 2020

News & Updates

Filter by Specialty:

Specialty:

Veliparib continues to show positive signals in ovarian cancer

Veliparib continues to show positive signals in ovarian cancer

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

Long-term PPI use does not increase GI cancer risk

Long-term PPI use does not increase GI cancer risk

Any polyps spell risk of colorectal cancer

Any polyps spell risk of colorectal cancer

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

Liquid biopsy promising for multidrug resistance detection in multiple myeloma

Liquid biopsy promising for multidrug resistance detection in multiple myeloma